With another earnings season upon us, The Fool's health care team is busy making sure investors know what to expect from their favorite companies this quarter, while also maintaining a focus on the long term.
In this segment, health care bureau chief Brenton Flynn tells us what to expect with Novartis (NVS 0.72%), which reports quarterly results on Wednesday. While the top line will likely experience a dip, Brenton likes what the company has done to keep costs low as it faces increased generic competition for its top-selling drug Diovan. He also highlights two of the company's newer drugs that he'll be keeping a close eye on, one of which should be of particular interest to Regeneron (REGN -1.75%) shareholders.
